Helen Femi Williams

On stage in Kreuzberg, Paul Kohlhaas put a familiar number to the room: it costs about $2.5 billion to bring a drug to market. Then he reframed it. That money doesn’t buy discovery. It buys the bureaucracy built around it. He had the figures to back it: a 90 to 96% trial failure rate, ten to fifteen years from hypot...